Invention Grant
- Patent Title: Heterocyclic compound and use thereof
-
Application No.: US17201878Application Date: 2021-03-15
-
Publication No.: US11702419B2Publication Date: 2023-07-18
- Inventor: Yuya Oguro , Shigemitsu Matsumoto , Takeshi Wakabayashi , Norihito Tokunaga , Taku Kamei , Mitsuhiro Ito , Satoshi Mikami , Masaki Seto , Shinji Morimoto , Shinji Nakamura , Sachie Takashima , Masataka Murakami , Masaki Daini , Makoto Kamata , Minoru Nakamura , Yasufumi Wada , Hiroyuki Kakei , Kazuaki Takami , Taisuke Tawaraishi , Jumpei Aida , Kouichi Iwanaga , Satoshi Yamamoto
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
- Priority: JP 18062939 2018.03.28
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61K9/20 ; A61K9/48 ; C07D471/04 ; A61P25/00
Abstract:
The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as described in the description, or a salt thereof.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as described in the description, or a salt thereof.
Public/Granted literature
- US20210332053A1 HETEROCYCLIC COMPOUND AND USE THEREOF Public/Granted day:2021-10-28
Information query
